WEBINAR: High-Throughput Antibody Discovery Targeting Glycoproteins for Apoptosis Induction in Cancer
By Ryan Kelly - November 12, 2019
Date: December 4, 2019 at 11AM ET (8AM PT)
Please join Sartorius and Abveris for an exclusive webinar featuring Tracey Mullen, Chief Operating Officer of Abveris, who will review an antibody discovery campaign targeting a glycoprotein for induction of apoptosis. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt® iQue platform will be detailed.
Who should attend:
Antibody discovery scientists and researchers engaged in therapeutic drug discovery for oncology indications.
Anyone interested in learning more about leveraging high-throughput flow cytometry analysis to advance research and development.
The use of monoclonal antibody-based drugs has proven very successful to target and treat cancer with more than half of late-stage clinical trial antibodies carrying an oncology indication. By employing multiple final formats, unconjugated or conjugated antibodies capitalize on methods of cell killing spanning from direct targeting and inhibition of cell survival pathways to shuttling and delivery of cytotoxic drugs. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution early stage characterization of lead antibody drug candidates prior to preclinical development.
Major advancements in high-throughput flow cytometry have enabled more exquisite antibody discovery within the oncology field by providing thorough analysis of on-cell antigen specificity and function earlier in the drug discovery process. In this webinar, an antibody discovery campaign targeting a glycoprotein for induction of apoptosis will be reviewed. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt iQue platform will be detailed.
Therapeutic antibody discovery for tough targets.
High-quality science and differentiated discovery technologies coordinated by experienced industry scientists, all the way from antigen design to antibody lead. Royalty-free formats available.